Amplia Therapeutics (ASX:ATX) reported an additional confirmed partial response in its ongoing ACCENT clinical trial evaluating the focal adhesion kinase inhibitor narmafotinib alongside standard chemotherapy, according to a Friday Australian bourse filing.
A confirmed partial response is defined as a tumor shrinkage exceeding 30%, sustained for at least two months, with no new lesions detected, the filing said.
The update lifts the objective response rate to 31%, surpassing the 23% benchmark seen with chemotherapy alone, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.